GNE.3230R1C70 Docket No.

Page 1 of 1

## Please Direct All Correspondence to Customer Number 30,313 JUL 1 1 2005

TRANSMITTAL LETTER

**UPPLEMENTAL INFORMATION DISCLOSURE STATEMENT** 

Applicant

Goddard, et al.

App. No

10/063,597

Filed

May 3, 2002

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

Sandra L. Wegert

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 8, 2005

(Date)

(aiser, Reg. No. 37,649

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- A Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references (X) for consideration:
  - Listing and enclosing 4 references. (X)
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Applicant** 

Goddard, et al.

App. No

10/063,597

Filed

May 3, 2002

For

SECRETED AND

TRANSMEMBRANE POLYPEPTIDES

AND NUCLEIC ACIDS ENCODING

THE SAME

Examiner

Sandra L. Wegert

Art Unit

1647

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a Supplemental Information Disclosure Statement by Applicant (PTO/SB/08 equivalent), listing 4 foreign patent references and/or non-patent literature to be considered by the Examiner.

This Supplemental Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

By:

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

1803801 070705 CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 8, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37.

## SUPPLEMENTAL INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 1

First Named Inventor Goddard, et al.

Art Unit 1647

Examiner Sandra L. Wegert

Attorney Docket No. GNE.3230R1C70

10/063,597

May 3, 2002

Application No.

Filing Date

LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	2	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	3	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	4	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

1803777 070705

Examiner Signature

**Date Considered** 

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.